TAINAN, Taiwan, Jan. 24 /Xinhua-PRNewswire/ -- For the third consecutive year, ScinoPharm Taiwan, Ltd. has witnessed monumental growth in its API (active pharmaceutical ingredient) business. The company’s total sales in 2005 reached US$31MM, compared to US$17MM in 2004 and US$7.6MM in 2003.
A number of biotech companies are collaborating with ScinoPharm on new drug development. So far, more than 40 NCE (new chemical entity) projects have been executed, with five of them in the Phase III stage of clinical trials. Among the NCE projects, one has been commercialized and one customer listed ScinoPharm as the only supplier in its NDA (new drug application). A second API for NCE projects is expected to be introduced in a year.
Meanwhile, ScinoPharm is also well positioned to capitalize on the generic business opportunities. To date, ScinoPharm has received 20 DMFs (drug master files) from the US FDA, and a combined total of 40 DMFs from Canada, Europe, Australia and New Zealand. More than 30 generic APIs have been developed with six of them being commercialized so far.
In addition, ScinoPharm offers a wide array of services including R&D, process development and manufacturing in compliance to cGMP to brand pharma. To that end, ScinoPharm has successfully established business partnership with seven of the top 10 brand companies.
Additional information is available from the company’s website at www.scinopharm.com .
CONTACT: Maggie Lin Tel: +866-6-505-2888 Ext. 2833 Fax: +886-6-505-2889 Email: magie.lin@scinopharm.com.tw WEB: www.scinopharm.com
Taiwan, Ltd.
ScinoPharm
CONTACT: Maggie Lin of ScinoPharm Taiwan, +866-6-505-2888 Ext. 2833, orfax, +886-6-505-2889, or magie.lin@scinopharm.com.tw
Web site: http://www.scinopharm.com/
